COOKIES USE
We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics.
 +info

Cookies config

  • Necessary

    The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.

    NameProveedorPropiedadFinalidadCaducidad+info
    _GRECAPTCHAgoogle.comOwnprovide antispam protection with the reCaptcha service6 months
    cc_cookie_acceptfidmag.orgOwnUsada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)1 any
    WEB_SESSIONfidmag.orgOwnCookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.al acabar la sessió

  • Analisys

    Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.

    NameProveedorPropiedadFinalidadCaducidad+info
    _gaGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics2 anys
    _gat_gtag_UA_141706552_1Google AnalyticsFrom third partiesCookie d'anàlisi o mesurament: Tracking per part de google per google analytics1 minut
    _gidGoogle AnalyticsFrom third partiesCookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds24 hores

ConfigureReject allAccept
Back to results
FI
4.369
2022 European Neuropsychopharmacology
The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study.
Martínez-Pinteño A, Mezquida G, Bioque M, López-Ilundain JM, Andreu-Bernabeu Á, Zorrilla I, Mané A, Rodríguez-Jiménez R, Corripio I, Sarró S, Ibáñez Á, Usall J, Rivero O, Gassó P, Leza JC, Cuesta MJ, Parellada M, González-Pinto A, Berrocoso E, Mas S, Bernardo M

Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.

Abstract

Neurotrophins have been proposed to be involved in biological mechanisms which might underlie different clinical outcomes in schizophrenia. The aims of the present study were to examine the BDNF/NGF plasma levels in a cohort of first-episode schizophrenia (FES) patients in remission as potential biological predictors of relapse; to study the associations between these neurotrophins and the symptomatology severity through different stages after a FES in two independent cohorts. 2EPs-Cohort: 69 first-episode in clinical remission were included. BDNF/NGF plasma levels and symptom severity were measured at enrollment and at 3-year or at the time of the second episode/relapse. FLAMM-PEPs-Cohort: 65 first-episodes were also included. BDNF/NGF and symptom severity were obtained at enrollment and 2-year follow-up. Symptomatology was assessed with the Marder-PANSS-Factor scores. Plasma neurotrophins did not differ significantly over time and neither BDNF/NGF were predictors of relapse. Besides, in remission stages, baseline BDNF levels showed significant correlations with both positive and negative symptoms (p<0.05); NGF, with negative symptomatology (p<0.01). Similarly, in the FLAMM-PEPs-Cohort, baseline BDNF/NGF levels showed significant correlations with negative symptoms (and not positive symptomatology) at follow-up (p<0.05). In both cohorts, lower levels correlated with higher symptom severity. Findings did not support a role for BDNF/NGF plasma levels as biomarkers of relapse in FES patients. Nevertheless, baseline BDNF/NGF may lead to be considered potentially useful biomarkers of long-term severity in schizophrenia and of the underlying illness traits, specially of negative symptomatology severity. More longitudinal studies in FES samples and adding a control group are warranted to replicate these findings.
We are part of
HH Província España
Contact us

Avda. Jordà, 8, 08035 Barcelona
Contact phone: 935 480 105
E-mail: fundacio@fidmag.org
Online contact 

           

 

Reconocimientos a la calidad y la excelencia
Última modificación: 22/03/2024